Colon-specific delivery of 5-aminosalicylic acid from chitosan-Ca-alginate microparticles

International Journal of Pharmaceutics

Volumn 342, Issue 1-2, 2007, Pages 124-136

  Mladenovska, K ^a   Raicki, R S ^a   Janevik, E I ^b   Ristoski, T ^b   Pavlova, M J ^b   Kavrakovski, Z ^a   Dodov, M G ^a   Goracinova, K ^a  

^a SS Cyril and Methodius University Faculty of Pharmacy   (Macedonia)

^b SS CYRIL AND METHODIUS UNIVERSITY   (Macedonia)

Author keywords

5 Aminosalicylic acid; Chitosan Ca alginate microparticles; Colon delivery; Controlled release; Inflammatory bowel diseases

Indexed keywords

CALCIUM ALGINATE; CHITOSAN; MESALAZINE; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; CONTROLLED DRUG RELEASE; DRUG BIOAVAILABILITY; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; GELATION; INFRARED SPECTROSCOPY; MALE; MICROENCAPSULATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RAT; ROENTGEN SPECTROSCOPY;

ALGINATES; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; B-LYMPHOCYTES; BODY WEIGHT; CALCIUM; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHYSICAL; CHITOSAN; COLITIS; COLON; CRYSTALLOGRAPHY, X-RAY; DELAYED-ACTION PREPARATIONS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; ELECTROCHEMISTRY; EXCIPIENTS; GELS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MESALAMINE; MICROSPHERES; ORGAN SIZE; PARTICLE SIZE; PEROXIDASE; RATS; RATS, WISTAR; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TISSUE DISTRIBUTION;

EID: 34547858901     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2007.05.028     Document Type: Article

References (57)

1. Acarturk F., and Takka S. Calcium alginate microparticles for oral administration. II. Effect of formulation factors on drug release and drug entrapment efficiency. J. Microencapsul. 16 (1999) 291-301
2. Bantel H., Berg C., Vieth M., Stolte M., Kruis W., and Schulze-Osthoff K. Mesalamine inhibits activation of transcription factor NF-κB in inflamed mucosa of patients with ulcerative colitis. Am. J. Gastroenterol. 95 (2000) 3452-3457
3. Bernkop-Schnurch A., Kast E.C., and Richter F.M. Improvement in the mucoadhesive properties of alginate by the covalent attachment of cysteine. J. Control. Rel. 71 (2001) 277-285
4. Bernstein C.N., Eaden J., Steinhart H., Munkholm P., and Gordon P.H. Cancer prevention in inflammatory bowel disease and the chemoprophylactic potential of 5-Aminosalicylic acid. Inflam. Bowel. Dis. 8 (2002) 356-361 Crohn's 7 Colitis Foundation of America, Inc.
5. Clemett D., and Markham A. Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease. Drugs 59 (2000) 929-956
6. Coppi G., Iannuccelli V., Leo E., Bernabei M.T., and Camoreni R. Chitosan-alginate microparticles as aprotein carrier. Drug. Dev. Ind. Pharm. 27 (2001) 393-400
7. D'Acquisto F., May M.J., and Ghosh S. Inhibition of nuclear factor kappa B (Nf-κB): an emerging theme in anti-inflammatory therapies. Mol. Intervent. 2 (2002) 22-35
8. De Jaeghere F., Allemann R., Doelker E., Gurny R., Cerny R., Galli B., Steulet A.F., Muller I., and Schutz H. pH-dependent dissolving nano- and microparticles for improved peroral delivery of a highly lipophilic compounds in dogs. AAPS Pharmsci. 3 1 (2001). http://www.pharmsci.org/ article 8 (http://www.pharmsci.org/)
9. Ewe K., Schwartz S., Petersen S., and Press A.C. Inflammation does not increase intraluminal pH in chronic inflammatory bowel disease. Dig. Dis. Sci. 44 (1999) 1434-1439
10. Fundueanu G., Esposito E., and Mihai D. Preparation and characterization of Ca-alginate microspheres by a new emulsification method. Int. J. Pharm. 170 (1998) 1-21
11. Gaserod O., Smidsrod O., and Skjak-Braek G. Microcapsules of alginate-chitosan I. A quantitative study of the interaction between alginate and chitosan. Biomaterials 19 (1998) 1815-1825
12. Gaserod O., Sannes A., and Skjak-Braek G. Microcapsules of alginate-chitosan II. A study of capsule stability and permeability. Biomaterials 20 (1999) 773-783
13. George M., and Abraham E.T. Polyionic hydrocolloids for the intestinal delivery of protein drugs: Alginate and chitosan-a review. J. Control. Rel. 114 (2006) 1-14
14. Giunchedi P., Torre M.L., Maggi L., Conti B., and Conte U. Cellulose acetate trimetillate ethylcellulose blends for nonsteroidal anti-inflammatory drug (NSAID) microspheres. J Microencapsul. 13 (1996) 89-98
15. Gombotz W.R., and Wee S.F. Protein release from alginate matrices. Adv. Drug. Del. Rev. 31 (1998) 267-285
16. Hartmann G., Bidlingmaier C., Siegmund B., Albrich S., Schulze J., Tschoep K., Eigler A., Lehr H.A., and Endres S. Specific type IV phopsphodiesterase inhibitor rolipram mitigates experimental colitis in mice. J. Pharmacol. Exp. Ther. 292 (2000) 22-30
17. He P., Davis S.S., and Illum L. Chitosan microspheres prepared by spray-drying. Int. J. Pharm. 187 (1999) 53-65
18. Huang M., Ma Z., Khor E., and Lim L.Y. Uptake of FITC-chitosan nanoparticles by A549 cells. Pharm. Res. 19 (2002) 1488-1494
19. Jagtap A.G., Shirke S.S., and Phadke A.S. Effect of polyherbal formulation on experimental models of inflammatory bowel disease. J. Ethnopharmacol. 90 (2004) 195-204
20. Kaiser G., Yan F., and Polk D. Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor κB activation in mouse colonocytes. Gastroenterology 116 (1999) 602-609
21. Khairou K.S., and Hassan R.M. Temperature-dependence of the electrical conductivity for cross-linked mono-and divalent metal-alginate complexes. High Perform. Polym. 14 (2002) 93-102
22. Krawiscz J.E., Sharon P., and Stenson W.F. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Gastroenterology 87 (1984) 1344-1350
23. Kuang J., Wills J.C., Trowbridge D.B., Gray P., Manning B.M., Eichwald E.J., Daynes R.A., and Kuwada S.K. Nuclear factor κB inhibitors induce adhesion-dependent colon cancer apoptosis: implications for metastasis. Cancer Res. 62 (2002) 6870-6878
24. Lamprecht A., Schafer U., and Lehr C.M. Characterization of microcapsules by confocal laser scanning microscopy: structure, capsule wall composition and encapsulation rate. Eur. J. Pharm. Biopharm. 49 (2000) 1-9
25. Lamprecht A., Schafer U., and Lehr C.M. Structural analysis of microparticles by confocal laser scanning microscopy. AAPS Pharm. Sci. Tech. 1 (2000) article 17
26. Lamprecht A., Ubrich N., Yamamoto H., Schafer U., Takeuchi H., Maincent P., Kawashima Y., and Lehr C.M. Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. J. Pharmacol. Exp. Ther. 299 (2001) 775-781
27. Lamprecht A., Schafer U., and Lehr C.M. Size-dependant bioadhesion of micro-and nanoparticulate carriers to the inflamed colonic mucosa. Pharm. Res. 18 (2001) 788-793
28. Liu L.-S., Liu S.-Q., Ng S.Y., Froix M., Ohno T., and Heller J. Controlled release of interleukin-2 for tumor immunotherapy using alginate/chitosan porous microspheres. J. Control. Rel. 43 (1997) 65-74
29. Liu X.D., Yu W.Y., Zhang Y., Xue W.M., Yu W.T., Xiong Y., Ma X.J., Chen Y., and Yuan Q. Characterization of structure and diffusion behaviour of Ca-alginate beads prepared with external or internal calcium sources. J. Microencapsul. 19 (2002) 775-782
30. Loftus E.V., Kane S.V., and Bjorkman D. Systematic review: short-term adverse effects of 5-ASA agents in treatment of ulcerative colitis. Aliment. Pharmacol. Ther. 19 (2004) 179-189
31. MacDermott M.D., and Richard P. Progress in understanding the mechanisms of action of 5-aminosalicylic acid. Am. J. Gastroenterol. 95 (2000) 3343-3345
32. Mladenovska K., Janevik E.I., Glavas D.M., Kumbaradzi E.F., and Goracinova K. Biodistribution studies of BSA loaded gelatin microspheres after peroral application. Int. J. Pharm. 242 (2002) 251-253
33. Mladenovska K., Janevik E.I., Glavas D.M., Kumbaradzi E.F., and Goracinova K. Biodistribution of 131I-BSA loaded gelatin microspheres after peroral application to BALB/c mice-particle size study. Acta Pharm. 53 (2003) 187-197
34. Morris G.P., Beck P.L., Herridge M.S., Depew W.T., Scewczuk M.R., and Wallace J.L. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 96 (1989) 795-803
35. Prakash A., and Markharm A. Oral delayed release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease. Drugs 57 (1999) 383-408
36. Ritger P., and Peppas N.A. A simple equation for description of solute release II. Fickian and anomalous release from swellable devices. J. Control. Rel. 5 (1987) 37-42
37. Rodriguez M., Antunez J.A., Taboada C., Seijo B., and Torres D. Colon-specific delivery of budenoside from microencapsulated cellulosic cores: evaluation of the efficacy against colonic inflammation in rats. J. Pharm. Pharmacol. 53 (2001) 1207-1215
38. Rogler G., Brand K., Vogl D., Page S., Hofmeister R., Andus T., Kneuchel R., Bauerle P.A., Scholmerich J., and Gross V. Nuclear factor κB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology 115 (1998) 357-369
39. Sandborn W.J., and Hanauer S.B. Systematic review:the pharmacokinetic of oral mesalazine formulations and mesalazine pro-drugs used in the menagement of ulcerative colitis. Aliment. Pharmacol. Ther. 17 (2003) 29-42
40. Sardar M., Roy I., and Gupta M.N. A smart bioconjugate of alginate and pectinase with unusual biological activity toward chitosan. Biotechnol. Prog. 19 (2003) 1654-1658
41. Schreiber S. Activation of nuclear factor κB as a target for anti-inflammatory therapy. Gut 441 (1999) 309-310
42. Schreiber S., Nikolaus S., and Hampe J. Activation of nuclear factor κB in inflammatory bowel disease. Gut 42 (1998) 477-484
43. Shin-ya Y., Lee M., Hinode H., and Kajiuchi T. Effects of N-acetylating degree on N-acetylated chitosan hydrolysis with commercially available and modified pectinases. Biochem. Eng. J. 7 (2001) 85-88
44. Takka S., and Acarturk F. Calcium alginate microparticles for oral administration. I. Effect of sodium alginate type on drug release and drug entrapment efficiency. J. Microencapsul. 16 (1999) 275-290
45. Tapia C., Escobar Z., Costa E., Sapag-Hagar J., Valenzuela F., Basualto C., Gai M.N., and Yazdani-Pedram M. Comparative studies on polyelectrolyte complex and mixtures of chitosan-carageenan as prolonged diltiazem clorhydrate release systems. Eur. J. Pharm. Biopharm. 57 (2004) 65-75
46. Tozaki H., Kamoike J., Tada C., Maruyama T., Terabe A., Suzuki T., Yamamoto A., and Muranishi S. Chitosan capsules for colon-specific drug delivery: improvement of insulin absorption from the rat colon. J. Pharm. Sci. 86 (1997) 1016-1021
47. Tozaki H., Odoriba T., Okada N., Fujita T., Terabe A., Suzuki T., Okabe S., Muranishi S., and Yamamoto A. Chitosan capsules for colon-specific drug delivery: enhanced localization of 5-aminosalicylic acid in the large intestine accelerates healing of TNBS-induced colitis in rats. J. Control. Rel. 82 (2002) 51-61
48. Turkoglu M., and Ugurlu T. In vitro evaluation of pectin-HPMC compression coated 5-aminosalicylic acid tablets for colonic delivery. Eur. J. Pharm. Biopharm. 53 (2002) 65-73
49. Ugwoke M.I., Verbeke N., and Konget R. Microencapsulation of apomorphine HCl with gelatin. Int. J. Pharm. 148 (1997) 23-32
50. Verziji J.M., and van Bodegraven A.A. Mesalazine-still a first line therapy. Gastroenterol. Eur. Pharmacother. (2003) 29-34
51. Wahl C., Liptay S., Adler G., and Schmid R.M. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J. Clin. Invest. 5 (1998) 1163-1174
52. Wittaya-areekul S., Kruenate J., and Prahsarn C. Preparation and in vitro evaluation of mucoadhesive properties of alginate/chitosan microparticles containing prednisolone. Int. J. Pharm. 312 (2006) 113-118
53. Yue G., Sun F.F., Dunn C., Yin K., and Wong P.Y. The 21-aminosteroid tirilazad mesylate can ameliorate inflammatory bowel disease in rats. J. Pharmacol. Exp. Ther. 276 (1996) 265-270
54. Zambito Y., and Di Colo G.D. Preparation and in vitro evaluation of chitosan matrices for colonic controlled drug delivery. J. Pharm. Pharmacol. Sci. 6 (2003) 274-281
55. Zerrouk N., Gines Dorado J.M., Arnaud P., and Chemtob C. Physical characteristics of inclusion compounds of 5-ASA in α and β cyclodextrins. Int. J. Pharm. 171 (1998) 19-29
56. Zhou S.Y., Fleisher D., Pao L.H., Li C., Winward B., and Zimmermann E.M. Intestinal metabolism and transport of 5-aminosalicylate. Drug. Metabol. Dispos. 27 (1999) 479-485
57. Zhou S.Y., Piyapolrungroj N., Pao L., Li C., Liu G., Zimmermann E., and Fleisher D. Regulation of paracellular absorption of cimetidine and 5-aminosalicylate in rat intestine. Pharm. Res. 16 (1999) 1781-1785